FDA PCAC July 2026: BPC-157, TB-500 and Five More Peptides Scheduled for Category 1 Review

What Is the July 2026 PCAC Hearing?

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is convening for a two-day formal review on 23–24 July 2026 at the FDA White Oak Campus in Silver Spring, Maryland. The session, announced in the Federal Register on 16 April 2026 under docket number FDA-2025-N-6895, will evaluate seven peptides for potential inclusion on the 503A Bulk Drug Substances Category 1 list — the list of substances formally approved for use in licensed US compounding pharmacy preparations under section 503A of the Federal Food, Drug, and Cosmetic Act.[1]

This hearing is the direct regulatory follow-on to the April 2026 Category 2 removals we covered in our FDA Peptide Reclassification 2026 guide. Removal from Category 2 was a procedural step that lifted the compounding prohibition; Category 1 approval through the PCAC process is the affirmative step that formally clears each compound for licensed compounding pharmacy use. Without a Category 1 vote, these peptides occupy a regulatory grey zone where compounding is neither explicitly prohibited nor explicitly permitted.

Full Two-Day Agenda: Which Peptides Are Under Review?

The PCAC will evaluate each substance individually, considering the existing published research, safety profile, clinical need evidence, and public comments submitted to the docket. The seven peptides are split across the two days as follows:[1][2]

All seven are reviewed in their free-base and acetate salt forms, which are the predominant forms used in compounding pharmacy preparations. The PCAC will consider whether each form individually meets the criteria for Category 1 placement, so it is possible that only one form of a given substance receives a favourable vote.

Research Context for Each Compound Under Review

The committee reviews the available published research base for each compound when formulating its recommendation. Below is a brief research-reference summary for each of the seven peptides, cited for their in vitro and animal model evidence base. These summaries are provided as scientific reference only and do not constitute claims about any product.

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric juice protein. Its research profile is one of the most extensively published among the seven peptides under review: over 80 peer-reviewed animal studies have investigated its effects in gastrointestinal, musculoskeletal, and wound models. Mechanistic research points to upregulation of growth-hormone receptor expression and modulation of nitric oxide pathways.[3] The PCAC's principal challenge for BPC-157 is the limited human data — as of 2026, only three small, uncontrolled human studies exist in the published literature, which the committee is expected to weigh carefully against the extensive preclinical record.

TB-500

TB-500 is a synthetic heptapeptide fragment (LKKTETQ) of Thymosin Beta-4, a ubiquitous 43-amino-acid protein found in most human and animal cells. Research interest centres on its role in actin-sequestering and cell migration under in vitro conditions. Animal model data includes wound healing, cardiac injury, and corneal repair studies. Like BPC-157, the human evidence base is limited, and the PCAC review is expected to focus on the mechanistic plausibility of its published effects and the characterisation of the acetate salt form used in preparations.[4]

MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide encoded within the 12S ribosomal RNA of the mitochondrial genome. Research published in Cell Metabolism (Lee et al., 2015) described its role in regulating glucose utilisation and metabolic homeostasis in mouse models.[5] More recent work has examined its expression across aging and exercise in human cohort studies. As a relatively novel compound with a growing but still early-stage human evidence base, its PCAC review is likely to hinge on safety characterisation and manufacturing standardisation.

KPV

KPV (Lys-Pro-Val) is a tripeptide C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In vitro research has explored its anti-inflammatory signalling properties, particularly in intestinal epithelial cell models. Its small size (three amino acids) gives it a well-characterised synthetic profile, which may work in its favour during the PCAC stability and safety analysis.[6]

DSIP (Emideltide)

DSIP (Delta Sleep-Inducing Peptide), also referred to as Emideltide in pharmacological literature, is a nonapeptide first isolated from rabbit cerebral venous blood in 1977. It has been studied in sleep, stress-axis modulation, and neuroprotective research models. Its research history is among the longest of the seven compounds, though the evidence base has gaps due to variable replication of early findings across independent laboratories.[7]

Semax

Semax (ACTH(4–7)-Pro-Gly-Pro) is a synthetic heptapeptide analogue of a fragment of adrenocorticotropic hormone. It has a notable clinical history in Russia, where an intranasal formulation has been licensed for use in stroke rehabilitation and cognitive conditions since the 1990s. This approved-use status in Russia means the PCAC review will have access to broader human-use data than is typical for research peptides, though the committee evaluates compounds under US regulatory standards independently of foreign approvals.[8]

Epitalon

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal gland peptide Epithalamin. It has been studied primarily in longevity and telomere biology research, following work by Vladimir Khavinson and colleagues in Russia across the 1990s and 2000s. Published animal and human studies (predominantly from Russian institutional research) report effects on telomerase activation and biomarkers of cellular ageing. The committee is expected to scrutinise the international replicability and methodological standards of the existing literature.[9]

What Are the Possible Outcomes of the PCAC Vote?

After evaluating the evidence for each compound, the PCAC members vote on a recommendation to the FDA. The FDA is not legally required to follow the committee's recommendation, but in practice its guidance strongly shapes subsequent regulatory action. The principal possible outcomes for each peptide are:

Regulatory Timeline: From Category 2 Removal to Category 1 Vote

What Does This Mean for UK Researchers?

The FDA's 503A Bulk Drug Substances framework is a US-specific regulatory mechanism governing licensed US compounding pharmacies. It does not apply outside the United States, and in particular has no direct legal force under UK or EU law. UK regulation of medicines and research reagents is administered independently by the Medicines and Healthcare products Regulatory Agency (MHRA) under the Human Medicines Regulations 2012 and associated secondary legislation.

For UK-based researchers purchasing compounds such as BPC-157, TB-500, MOTS-c, KPV, DSIP, or Semax as research reagents, the applicable legal framework is entirely UK domestic law. None of these compounds are scheduled controlled substances under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. Velox Peptides supplies all compounds strictly as research reagents for in vitro laboratory research use only, under our Research Use Policy.

The PCAC review does, however, carry indirect significance for UK researchers in two ways. First, the safety and characterisation data assembled for the PCAC docket will enter the public domain and contribute to the published evidence base for these compounds. Second, PCAC outcomes often serve as a reference point for regulatory discussions in other jurisdictions, including MHRA horizon-scanning. Our broader guide on whether research peptides are legal in the UK and the FDA Peptide Reclassification 2026 context guide are useful companion reads.

Frequently Asked Questions